These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of food on kinetics of 8-methoxsalen. Ehrsson H; Nilsson SO; Ehrnebo M; Wallin I; Wennersten G Clin Pharmacol Ther; 1979 Feb; 25(2):167-71. PubMed ID: 759069 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and relative bioavailability of vinylbital in man after oral and rectal administration. Breimer DD; de Boer AG Arzneimittelforschung; 1976; 26(3):448-54. PubMed ID: 989344 [TBL] [Abstract][Full Text] [Related]
7. Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro. Gibbs JP; Yang JS; Slattery JT Drug Metab Dispos; 1998 Jan; 26(1):52-5. PubMed ID: 9443852 [TBL] [Abstract][Full Text] [Related]
9. [Varying course of pancytopenia after busulfan treatment of chronic myelocytic leukemia (CML)]. Krug K; Stenzel L Folia Haematol Int Mag Klin Morphol Blutforsch; 1978; 105(2):181-7. PubMed ID: 79522 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. Hassan M; Ehrsson H; Wallin I; Eksborg S Eur J Drug Metab Pharmacokinet; 1988; 13(4):301-5. PubMed ID: 3243326 [TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic myeloid leukemia with repeated single doses of busulfan. Sullivan JR; Hurley TH; Bolton JH Cancer Treat Rep; 1977; 61(1):43-5. PubMed ID: 266418 [TBL] [Abstract][Full Text] [Related]
13. Urinary metabolites of busulfan in the rat. Hassan M; Ehrsson H Drug Metab Dispos; 1987; 15(3):399-402. PubMed ID: 2886318 [TBL] [Abstract][Full Text] [Related]
14. Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation. Cawello W; Braun M; Andreas JO Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):475-481. PubMed ID: 29332198 [TBL] [Abstract][Full Text] [Related]
15. Acute myeloblastic transformation after busulfan treatment of chronic myelocytic leukemia. RITZ ND; KRIM M N Y State J Med; 1959 Dec; 59():4602-8. PubMed ID: 14437631 [No Abstract] [Full Text] [Related]
16. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Poonkuzhali B; Chandy M; Srivastava A; Dennison D; Krishnamoorthy R Drug Metab Dispos; 2001 Mar; 29(3):264-7. PubMed ID: 11181493 [TBL] [Abstract][Full Text] [Related]
17. A 13-years remission in chronic myelocytic leukemia after a single course of busulfan. Weinberger A; Benjamin D; Douer D; Barabash G; Djaldetti M; Pinkhas J Acta Haematol; 1978; 59(6):354-9. PubMed ID: 97894 [TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. Diestelhorst C; Boos J; McCune JS; Russell J; Kangarloo SB; Hempel G Cancer Chemother Pharmacol; 2013 Nov; 72(5):991-1000. PubMed ID: 24061863 [TBL] [Abstract][Full Text] [Related]
19. Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization. Effting C; de Moraes Arantes A; Queiroz Labre LV; Carneiro WJ; de Oliveira Neto JR; Bariani C; Rodrigues CR; Rodrigues AR; Cunha LC Ther Drug Monit; 2015 Feb; 37(1):66-70. PubMed ID: 25588069 [TBL] [Abstract][Full Text] [Related]